title: [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment].
abstract: A combination of radiotherapy and chemotherapy is a usual treatment method for malignant head and neck tumors, however chemoradiotherapy is associated with hematopoietic impairment and serious stomatitis in patients. The clinical effects and evaluation of hematopoietic activity (e.g., leukocyte count) and the degree of stomatitis under adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer were investigated for preoperative cancer therapy. In order to evaluate the clinical effects of Ancer 20 injection with regard to hematopoietic activity and the degree of stomatitis, a clinical study was performed for 18 patients with oral cancer in our department. The 18 patients, who had oral squamous cell carcinomas (5 of the tongue, 4 of the mandibular gingiva, 3 of the maxillary gingiva, 1 of the floor of the mouth, 3 of the buccal mucosa, and 2 others), were treated with this combination of adjuvant therapy with Ancer 20 injection, from March, 1991 to March, 1997. They were injected with Ancer 20 (twice a week, 40 micrograms) during the cancer treatment period. We investigated hematopoietic activity, (e.g., leukocyte and platelet counts) and the degree of stomatitis periodically, before and after the combined radiotherapy and chemotherapy treatment period. It was found that in the patients who were treated with Ancer 20 injection, the decrease in leukocyte and platelet counts was prevented and the condition of stomatitis was improved. These results suggest that Ancer 20 injection may generally improve various dysfunctions due to hematopoietic impairment by radiotherapy combined with chemotherapy, and improve immunological factors. We conclude that Ancer 20 injection is a useful adjuvant treatment for oral cancer.
authors.affiliation: Dept. of Oral and Maxillofacial Surgery, Gifu University, School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Okutomi
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: H
authors.initials: H
authors.lastname: Ichihara
authors.forename: I
authors.initials: I
authors.lastname: Hyodo
authors.forename: H
authors.initials: H
authors.lastname: Fujitsuka
authors.forename: S
authors.initials: S
authors.lastname: Yasuda
authors.forename: N
authors.initials: N
authors.lastname: Tatematsu
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000517:prevention & control*; D008055:Lipids / Q000008:administration & dosage; D008351:Mannans / Q000008:administration & dosage; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D013280:Stomatitis / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D008055:Lipids; D008351:Mannans; D011837:Radiation-Protective Agents; C031208:specific substance maruyama